



ASX Announcement

16 March 2026

Results of Extraordinary General Meeting

Sydney, Australia; 16 March 2026: Cambium Bio Limited (ASX:CMB) ("Cambium Bio", "Cambium" or "Company"), a clinical-stage regenerative medicine company focused on ophthalmology and tissue repair, advises that the results of its Extraordinary General Meeting (EGM) that was held today, are set out in the attached document in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) (the "Act") and ASX Listing Rule 3.13.2. All resolutions were decided by way of poll. All resolutions were carried. Details of the resolutions and the proxies received in respect of each resolution are set out in the attached proxy summary.

This announcement was authorised by the Board of Directors of Cambium Bio Limited.

- END -

For further information, please contact:

Acclime Australia – Company Secretary
Email: info@cambium.bio

Cambium Bio Limited
Unit 2.06/31 Lexington Drive, Bella Vista, NSW 2153 Australia
ABN 13 127 035 358
Phone: 1300 995 098
www.cambium.bio

About Cambium Bio Limited

Cambium Bio Limited (ASX:CMB) is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications. The Company's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. Cambium Bio's lead product candidate, Elate Ocular®, is being developed to address significant unmet medical needs in the treatment of dry eye disease. In addition, the Company's stem cell platform, Progenza™, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. Cambium Bio is committed to advancing its pipeline through clinical development and commercialisation, with the goal of providing transformative treatments to improve patient outcomes. For more information about the Company and its programs, please visit www.cambium.bio.

CAMBIUM BIO LIMITED

GENERAL MEETING
Monday, 16 March, 2026

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

Resolution Voted on at the meeting			Proxy Votes (as at proxy close)				Total votes cast in the poll (where applicable)			
No	Short Description	Strike Y/N/NA	<i>For</i>	<i>Against</i>	<i>Discretionary (OpenVotes)</i>	<i>Abstain</i>	<i>For</i>	<i>Against</i>	<i>Abstain **</i>	<i>Result</i>
1	APPROVAL TO ISSUE PLACEMENT SHARES TO ZHENG YANG BIOMEDICAL TECHNOLOGY CO., LTD (ZYBT)	NA	7,874,811 99.12%	58,011 0.73%	11,818 0.15%	161,173	7,886,629 99.27%	58,011 0.73%	161,173	Carried
2	APPROVAL TO ISSUE UP TO AUD\$10,000,000 WORTH OF SHARES	NA	14,794,403 99.56%	55,321 0.37%	10,508 0.07%	162,173	14,804,911 99.63%	55,321 0.37%	162,173	Carried

** - Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item